Medpace Announces Webinar on Integrated Cell and Gene Therapy Development
Medpace is hosting a webinar featuring experts from its medical, laboratory, and clinical operations teams to discuss risk mitigation in cell and gene therapy clinical trials.
Stocks · News reference
Medpace is hosting a webinar focused on integrated, cross-functional strategies for managing glomerular disease clinical trials.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Medpace is hosting a webinar featuring experts from its medical, laboratory, and clinical operations teams to discuss risk mitigation in cell and gene therapy clinical trials.
ResMed (RMD) delivered solid first-quarter fiscal 2027 results with adjusted EPS of $2.91, up 14% year-over-year and beating consensus by 9%. Revenues grew 6% to $1.41 billion, driven by sustained demand for sleep devices and masks. Gross margins expanded 50 basis points to 62.5% from productivity gains. However, the company faced headwinds from discontinued Astral life-support device sales and the MatrixCare divestiture. RMD maintained its fiscal 2027 guidance for 5-7% core constant-currency revenue growth and $12.00-$12.25 adjusted EPS.
Medpace has scheduled a webinar for November 9, 2026, focused on operational strategies and integrated technology for diabetes clinical trials.
Several financial institutions, including UBS, Barclays, and TD Cowen, have updated their price targets and maintained ratings for Medpace Holdings, Inc. following recent performance assessments.
Barclays has maintained its hold rating on Medpace Holdings, Inc. and increased its price target to $675.